Key result
Atorvastatin treatment for one month significantly reduced nitrite plasma levels compared to control in patients with peripheral artery disease (5.7 vs 13.1 µM; P<0.001).
Why the study?
Does atorvastatin improve endothelial function and total-cholesterol/HDL-cholesterol ratio in patients with peripheral artery disease?
RCT (n=150)
randomised
Does atorvastatin improve endothelial function and total-cholesterol/HDL-cholesterol ratio in patients with peripheral artery disease?
In patients with peripheral artery disease, one month of atorvastatin therapy improves endothelial function, which correlates strongly with reductions in the total-cholesterol/HDL-cholesterol ratio.
Supports short-term atorvastatin for endothelial gains in PAD; confirms lipid-ratio correlation in RCT evidence.
Aims. To evaluate the effects of variations of total-cholesterol/HDL-cholesterol ratio and the effects of the atorvastatin on endothelial function in peripheral artery disease (PAD). Material and Methods. A prospective, randomised controlled study was carried out in 150 PAD patients. Patients randomized to the control group (n = 75) were treated with antiplatelet drugs, angiotensin-converting-enzyme inhibitors and cardiovascular-risk-factor control. Experimental group (n = 75) also received treatment with atorvastatin for a month. It was determined baseline nitrite plasma levels and total-cholesterol/HDL-cholesterol ratio and after one month of treatment in both groups. It was also analysed the correlation between the gradient of nitrite levels and the differential of total-cholesterol/HDL ratio in treatment group. Results. After a month, a reduction in nitrite levels was detected in treatment group (11.88 ± 7.8 μM versus 5.7 ± 1.8 μM, P < 0.0001). It was shown a higher decrease in nitrite plasma levels in the atorvastatin group finding lower levels assessments (5.7 ± 1.8 μM versus 13.1 ± 9.1 μM, resp., P < 0.001). A significant reduction in total-cholesterol/HDL-cholesterol ratio was observed in statin group after treatment (P < 0.0001). A strong correlation was found between the gradient of nitrite levels and the differential of total-cholesterol/HDL-cholesterol ratio in atorvastatin group (r = 0.7; P < 0.001). Conclusions. Improvement of nitrite levels are associated with decreased total cholesterol/HDL ratio values in PAD patients treated with atorvastatin.
No takes yet. Share an insight, caveat, or question.
Bleda et al. (2012) conducted an RCT in Peripheral artery disease (PAD) (n=150). Atorvastatin vs. Antiplatelet drugs, angiotensin-converting-enzyme inhibitors and cardiovascular-risk-factor control was evaluated on Nitrite plasma levels (p=<0.001). Atorvastatin treatment for one month significantly reduced nitrite plasma levels compared to control in patients with peripheral artery disease (5.7 vs 13.1 µM; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: